trending Market Intelligence /marketintelligence/en/news-insights/trending/HFOcNw34Iz2k_1afBxE7RQ2 content esgSubNav
In This List

Roche purchases shares in $4.3B Spark tender offer; deal on track to completion

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Roche purchases shares in $4.3B Spark tender offer; deal on track to completion

Roche Holding AG said it accepted for payment all shares in the tender offer to acquire Spark Therapeutics Inc. in a $4.3 billion all-cash deal.

Citibank NA, the depositary for the tender offer, advised the Swiss pharmaceutical company that about 23,276,342 of Spark's common shares were validly tendered and not validly withdrawn, representing about 60.4% of the latter's outstanding common stock.

Basel-based Roche launched the buyout offer to acquire all outstanding shares of the Philadelphia-based gene therapy maker for $114.50 apiece in March.

The tender offer expired at 5:00 p.m. ET on Dec. 16 and was not extended. The offer has been extended 10x to allow for further regulatory scrutiny into the deal.

On Dec. 16, Roche finally cleared regulatory hurdles after the U.K. Competition and Markets Authority and the U.S. Federal Trade Commission granted unconditional clearance to the transaction.

Roche said it plans to complete the takeover Dec. 17 without a vote or meeting of Spark's shareholders.

After deal closing, Spark will become a wholly owned unit of Roche. Spark's shares will no longer trade on the Nasdaq Stock Market.